JPRN-jRCT1031210620招募中未知
Effect of oral semaglutide on glucose variability and oxidative stress in type 2 diabetes patients
Ohara Makoto0 个研究点目标入组 58 人开始时间: 2022年2月18日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 58
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •a diagnosis of type 2 diabetes mellitus
- •1) HbA1c 7.0% or more
- •2) treatment with DPP-4 inhibitors for 12weeks or longer
- •3) written informed consent
- •4) 20 years and over
排除标准
- •1)the use of steroids or anti-inflammatory drugs,
- •2)diabetic ketosis and coma within 3 months before the study,
- •3)severe infection, severe trauma, pre-and post-operation,
- •4)an estimated glomerular filtration rate are within 30mL/min/1.73m2,
- •5)malignancy,
- •6)pregnancy
- •7)Patients who are judged as inappropriate for inclusion by phsicians
- •8)Patients using implantable medical devices such as cardiac pacemakers
研究者
相似试验
已完成
不适用
Effect of oral semaglutide on glucose variability and oxidative stress in type 2 diabetes patientsType 2 diabetes mellitusJPRN-UMIN000046938Showa University School of Medicine, Division of Diabetes and Endocrinology, Department of Internal Medicine60
已完成
不适用
Effect of semaglutide on glucose variability and oxidative stress in type 2 diabetes patientsJPRN-UMIN000042670Showa University School of Medicine, Division of Diabetes and Endocrinology, Department of Internal Medicine42
招募中
不适用
Effect of Semaglutide 0.25mg on glycemic controls in type2 diabetes patients compared with dulaglutide 0.75mg.type2 diabetesJPRN-UMIN000042482Saiseikai Yokohamashi Nanbu Hospital20
进行中（未招募）
1 期
A research study to compare semaglutide to insulin aspart, when taken together with metformin and insulin glargine, in people with type 2 diabetesMedDRA version: 21.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 100000004861Diabetes Mellitus, Type 2EUCTR2017-003219-20-CZovo Nordisk A/S2,043
进行中（未招募）
1 期
A research study to compare semaglutide to insulin aspart, when taken together with metformin and insulin glargine, in people with type 2 diabetesMedDRA version: 20.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 100000004861Diabetes Mellitus, Type 2EUCTR2017-003219-20-ESovo Nordisk A/S2,274